Ben is the founder and CEO of Cellibre, a cellular agriculture company that is ushering in the next great industrial revolution by treating biology as a manufacturing technology, turning cells into specialized, sustainable factories for the manufacture of globally significant products at scale. 

Ben formally worked with Dr. J Craig Venter and Nobel Laureate Dr. Ham Smith as the Vice President of Corporate Development and Strategy at Synthetic Genomics (SGI) where he was responsible for defining, evolving and implementing SGI’s strategy across all of its franchises. 

Ben joined SGI from Millennium Health, a leading medication solutions company focused on solving the opioid epidemic, where he led the strategy and corporate development efforts. Prior to joining industry, Ben had a nine-year tenure on Wall Street (most recently with J.P. Morgan’s healthcare investment banking group), where he executed over $20 billion in transactions. 

Ben earned his MBA from Carnegie Mellon University’s Tepper School of Business and his B.S. in Mechanical Engineering from Case Western Reserve University. He is also the co-founder of Divitempus Ventures, ConvenCare and the 32/21 Foundation.